Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
Luigi Tarantini(Santa Maria Nuova Hospital), Pompilio Faggiano(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Daniella Bovelli(Azienda Ospedaliera S.Maria), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Giovanni Cioffi(Casa di Cura Villa Bianca), L Boccardi, Fausto Tuccia, Giulia Russo, Chiara Lestuzzi
Cited by 116
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
|Annals of Oncology|2010|168
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164